- How Doctors Prescribing Meds Based on Drug Company Payoffs is Further Evidence of Systemic Failure (Liberty Blitzkrieg, Dec 8, 2014):
When the drug maker Genentech introduced a major product in 2006, it found itself in an awkward position: persuading eye doctors to start using its new more expensive drug instead of a popular cheaper version that the company already sold.
Ophthalmologists had been enthusiastically using the company’s cancer drug Avastin, which cost about $50 a dose, to treat a common eye disease in the elderly, wet macular degeneration. Then Genentech introduced Lucentis, a nearly equivalent drug that cost $2,000 a dose and was approved specifically to treat the disease.
Now, a new federal database shows that many of the doctors who were the top billers for Lucentis were also among the highest-paid consultants for Genentech, earning thousands of dollars to help promote the drug. The data raises questions about whether financial relationships between doctors and drug companies influence treatment decisions, even though physicians maintain they cannot be swayed.
Half of the 20 doctors who received the most money from Genentech to promote Lucentis in 2013 were among the highest users of the drug in 2012, billing for higher amounts of Lucentis than 75 percent of their peers. The figures were compiled from two federal databases that covered different periods, and it is not known whether or how much Genentech paid the doctors in 2012.
– From the New York Times article: Paid to Promote Eye Drug, and Prescribing It Widely
The topic at the heart of the following post is not a commonly discussed one here at Liberty Blitzkrieg. It has to do with big corporate money influencing and corrupting the medical profession. The reason I chose to highlight this particular article, is because it perfectly puts into focus two of the most important macro cancers plaguing these United States today: A complete loss of ethics, and the dangers of over-centralization/corporatization. Continue reading »